PDF
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years
Organization: United States Centers for Disease Control (CDC)Published: 2022
"Receipt of 2 doses of Pfizer-BioNTech COVID-19 vaccine has been shown to be effective in preventing infection with the SARS-CoV-2 B.1.617.2 (Delta) variant in persons aged ≥12 years.Two doses of Pfizer-BioNTech COVID-19 vaccine reduced the risk of Omicron infection by 31% among children aged 5–11 years and by 59% among persons aged 12–15 years. All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations." - Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022
Additional Authors: Lauren Grant, Andrew L. Phillips, Katherine Ellingson, Maria V. Ferraris, Lindsay B. LeClair, Clare Mathenge, Young M. Yoo, Matthew S. Thiese, Lynn B. Gerald, Natasha Schaefer Solle, Zuha Jeddy, Leah Odame-Bamfo, Josephine Mak, Kurt T. Hegmann, Joe K. Gerald, Jezahel S. Ochoa, Mark Berry, Spencer Rose, Julie Mayo Lamberte, Purnima Madhivanan, Felipe A. Pubillones, Ramona P. Rai, Kayan Dunnigan, John T. Jones, Karl Krupp, Laura J. Edwards, Edward J. Bedrick, Brian E. Sokol, Ashley Lowe, Hilary McLeland-Wieser, Krystal S. Jovel, Deanna E. Fleary, Sana M. Khan, Brandon Poe, James Hollister, Joanna Lopez, Patrick Rivers, Shawn Beitel, Harmony L. Tyner, Allison L. Naleway, Lauren E.W. Olsho, Alberto J. Caban-Martinez, Jefferey L. Burgess, Mark G. Thompson, Manjusha Gaglani
Product Type: Report
Category:
Vaccine Safety and Development,Research and Development,Vaccine Effectiveness and Efficacy,Specific Populations,Children,School-aged,Adolescents,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19 Vaccine Safety and DevelopmentResearch and Development
Vaccine Effectiveness and Efficacy
Specific Populations
Children
School-aged
Adolescents
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Population: School-aged Children
Adolescents
Region: United States
Audio
LinkResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.